STRONG PARTNERSHIPS
Alliances and joint-ventures
Vifor Pharma constantly strengthens its worldwide leading position in the global i.v. iron market. With Fresenius Medical Care, the world’s largest provider of dialysis products and services, Vifor Pharma entered into a strategic joint-venture for dialysis to market and distribute the two iron products Venofer® and Ferinject® in Europe , Middle East , Africa and Latin America. In the US and Canada Vifor Pharma exclusively licenses Venofer® and Injectafer® (US brand for Ferinject®) to Luitpold Pharmaceuticals, Inc. who have entered into a corresponding agreement with Fresenius Medical Care.
Through the Canadian Aspreva Pharmaceuticals Corporation (acquired by Galenica in 2008), Vifor Pharma has a successful collaboration with Roche, using its knowledge and expertise in the field of autoimmune diseases to research the efficacy of the Roche drug CellCept in the treatment of lupus nephritis, a chronic autoimmune disease. In 2003, Aspreva secured the worldwide rights (ex Japan) to develop and commercialise CellCept for all applications in connection with autoimmune diseases.
Back to 'Company'
Through the Canadian Aspreva Pharmaceuticals Corporation (acquired by Galenica in 2008), Vifor Pharma has a successful collaboration with Roche, using its knowledge and expertise in the field of autoimmune diseases to research the efficacy of the Roche drug CellCept in the treatment of lupus nephritis, a chronic autoimmune disease. In 2003, Aspreva secured the worldwide rights (ex Japan) to develop and commercialise CellCept for all applications in connection with autoimmune diseases.
Back to 'Company'